CRYSTALSFIRST AND NEXMR JOIN FORCES TO SUPERCHARGE FRAGMENT-BASED DRUG DISCOVERY 24th July 2023 – CrystalsFirst GmbH, a leading provider of innovative crystallography solutions, and NexMR GmbH, a technology company specializing in high-performance Nuclear Magnetic Resonance (NMR), are thrilled to announce their strategic collaboration. This partnership aims to redefine the field
CRYSTALSFIRST ESTABLISHES PARTNERSHIP WITH AKTTYVA THERAPEUTICS TO SUPPORT AI-POWERED DRUG DISCOVERY PROGRAMS Hamburg, Germany February 23, 2023 — CrystalsFirst, a leading provider of small-molecule drug discovery services, announced today the signing of a drug discovery service agreement withAkttyva Therapeutics. Under the terms of the agreement, CrystalsFirst will apply its proprietary
Chemical Space Docking: Odyssey to Unlock Relevant Compounds Advances in technology have led to a major breakthrough in chemical space exploration. By combining computational and experimental methods, researchers are unlocking the full potential of structure-based drug discovery. One highly regarded approach is Chemical Space Docking, which plays a crucial role
Our fragment-to-hit approach that has been published in the Journal of Medicinal Chemistry. Fragment-based drug discovery (FBDD) has proven to be an effective method in finding therapeutics for difficult drug targets. We present a cutting-edge approach to identify active molecules in purchasable chemical space. This method begins with four small-molecule
Fragment-Based Drug Discovery — Hitting Targets Using the Right Chemistry and Expertise Alliances Fragment-Based Drug Discovery (FBDD) has gained significant attention and importance in recent years as a method for identifying and optimizing hits for drug development. It has led to the development of approved therapeutics and numerous drug candidates,
Unlocking chemical matter on scale Fragment-based drug discovery (FBDD) has become an indispensable resource for medicinal chemists in searching for lead candidates. To effectively evaluate fragments, various biophysical methods are applied using a cascade approach as a pre-screening step before determining protein-ligand interactions. This approach has been found to be
September 6, 2023
This year, we celebrate a significant achievement as CrystalsFirst reaches its 5th Anniversary!Â
For the past five years, CrystalsFirst has been leading the way in pushing the boundaries of structural biology and drug discovery. Our relentless dedication to innovation and outstanding performance has positioned us as a pivotal figure in the field of drug discovery, establishing groundbreaking benchmarks for drug discovery.
We are proud to report our remarkable achievements over the past five years:
THE SMARTSOAK® ADVANTAGE
FOR COVALENT DRUG DISCOVERY
SmartSoak provides significant advantages for for covalent fragment-based drug discovery enabling rapid determination of co-structures for optimization:Â
Conventional soaking fails to modify the cysteine in the active site
SmartSoak setup enables the covalent modification of cysteine
High resolution co-structure of human protein with novel MOA at 1.3 Ă…
July 24, 2023
CrystalsFirst and NexMR Join Forces to Supercharge
Fragment-Based Drug Discovery
“This collaboration allows us to provide our clients with a more holistic approach, combining NexMR’s ultrafast NMR fragment screening technology with our world-class protein crystallography expertise. Together, we aim to accelerate the discovery of novel therapeutics.” Dr. Serghei Glinca, CEO of CrystalsFirst GmbH.
May 22, 2023
Co-crystal soaking using our technology SMARTSOAK® is specifically designed for drug discovery purposes:Â
Contact us today to learn more about our soaking applications!
THE CHALLENGE OF THE INDUSTRY: ACCESS TO CHEMICAL MATTER
The challenge of the industry remains – access to chemical matter. The Drug Discovery Chemistry conference was full of highlights focusing mainly on enabling technologies and platforms that unlock chemical matter. Read our perspective.Â
March 31, 2023
CrystalsFirst’s innovative platform to unlock chemical matter using FBDD has been featured in the renown “Photon Science 2022 – Highlights and Annual Report” published by Europe’s largest synchrotron DESY.Â
We believe that putting science first and empower each individual is essential for a great atmosphere and productivity. But we wanted to measure our results.Â
A GREAT PLACE TO WORK
The results of the “Employee Satisfaction Survey” lead to an index of 80, which reflects a the highest possible level of satisfaction: “very high satisfaction”.Â
Happy employees, happy customers
February 23, 2023
CrystalsFirst Establishes Partnership With Akttyva Therapeutics To SupporAI-Powered Drug Discovery Programs​
We are excited to announce today the signing of a drug discovery service agreement with Akttyva Therapeutics to unlock the full therapeutic potential of the human kinome.Â
January 31, 2023
EXPANDET PROTEIN PRODUCTION CAPABILITIES
Introducing our new state-of-the-art protein production capabilities, specifically designed for drug discovery purposes:Â
Contact us today to learn more about our new protein production facility and how we can help you achieve your research goals!
THE IMPACT OF THE PROTEIN DATA BANK
Our recent blog post, we discuss how the deposited structural data is helping to develop new drugs, supporting biomedical research, and providing relevant data for Artificial Intelligence and Machine Learning methods.Â
January 23, 2023
November 17, 2023
By loading the video, you agree to YouTube's privacy policy.
Learn more
By loading the video, you agree to YouTube's privacy policy.
Learn more
November 25, 2023
Our Head of Protein Sciences Moritz Ruf will be attending the conference on “Engineering recombinant proteins for structural and functional studies”.Â
November 21, 2023
Our head of AI Artem German will give a talk at the FoldForum on the role of generative AI for drug discovery. CrystalsFirst’s MAGNET platform utilizes generative AI to unlock chemical matter using “crystal structure first” approach.
August 11, 2023
CrystalsFirst will be attending ACS Fall 2023 in San Francisco
August 13-17. We will present our solution to unlock chemical matter using “crystal structure first” fragment hits.Â
